The Medicines and Healthcare products Regulatory Agency (MHRA) is to review a submission for exagamglogene autotemcel (exa-cel), from USA-based Vertex Pharmaceu 27 January 2023
Oxford, UK-headquartered oncology start-up Grey Wolf Therapeutics has raised $49 million in a series B financing led by Pfizer Ventures and Earlybird Venture Ca 26 January 2023
Autoimmune disease specialist EVOQ Therapeutics has appointed David Giljohann as chief executive, replacing co-founder William Brinkerhoff, who has served as CE 10 January 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.